foxo4-dri senescence 10mg | Senolytic Research Peptide FOXO4-DRI Peptide - 10 mg
FOXO4 DRI Peptide 10 mg FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data FOXO4 DRI: A Breakthrough Peptide Targeting Aging at Its Roots PARTICLE, s. r. o. Tools to eliminate senescent cells Nature The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $5.77 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8




